share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3:募資說明書
美股SEC公告 ·  05/16 12:45
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated March 23, 2023, with details from its quarterly report filed on the same date. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA,' with the last reported sales price being $0.4408 per share as of May 14, 2024. The supplement emphasizes that investing in Panbela's securities involves a high degree of risk and that the SEC has not approved or disapproved the accuracy or adequacy of the prospectus supplement or the Prospectus. The company's quarterly report reveals a net loss of $7.1 million for the quarter ended March 31, 2024, and a decrease in cash and cash equivalents from $2.578 million to $262,000. Panbela Therapeutics, Inc. continues to incur losses and negative cash flows from operating activities, raising substantial doubt about its ability to continue as a going concern without additional financing.
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated March 23, 2023, with details from its quarterly report filed on the same date. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA,' with the last reported sales price being $0.4408 per share as of May 14, 2024. The supplement emphasizes that investing in Panbela's securities involves a high degree of risk and that the SEC has not approved or disapproved the accuracy or adequacy of the prospectus supplement or the Prospectus. The company's quarterly report reveals a net loss of $7.1 million for the quarter ended March 31, 2024, and a decrease in cash and cash equivalents from $2.578 million to $262,000. Panbela Therapeutics, Inc. continues to incur losses and negative cash flows from operating activities, raising substantial doubt about its ability to continue as a going concern without additional financing.
Panbela Therapeutics, Inc.於2024年5月15日提交了招股說明書補充文件,以更新和補充其先前於2023年3月23日提交的招股說明書中的信息,詳細信息來自於同日提交的季度報告。該補充文件涉及發行先前發行的認股權證基礎的4,776,038股普通股。該公司的普通股在OTCQB上市,股票代碼爲 “PBLA”,截至2024年5月14日,上次公佈的銷售價格爲每股0.4408美元。該補編強調,投資Panbela的證券涉及高度的風險,美國證券交易委員會尚未批准或不批准招股說明書補充文件或招股說明書的準確性或充分性。該公司的季度報告顯示,截至2024年3月31日的季度淨虧損710萬美元,現金及現金等價物從25.78萬美元減少至26.2萬美元。Panbela Therapeutics, Inc.繼續因經營活動蒙受虧損和負現金流,這使人們對其在沒有額外融資的情況下繼續經營的能力產生了嚴重懷疑。
Panbela Therapeutics, Inc.於2024年5月15日提交了招股說明書補充文件,以更新和補充其先前於2023年3月23日提交的招股說明書中的信息,詳細信息來自於同日提交的季度報告。該補充文件涉及發行先前發行的認股權證基礎的4,776,038股普通股。該公司的普通股在OTCQB上市,股票代碼爲 “PBLA”,截至2024年5月14日,上次公佈的銷售價格爲每股0.4408美元。該補編強調,投資Panbela的證券涉及高度的風險,美國證券交易委員會尚未批准或不批准招股說明書補充文件或招股說明書的準確性或充分性。該公司的季度報告顯示,截至2024年3月31日的季度淨虧損710萬美元,現金及現金等價物從25.78萬美元減少至26.2萬美元。Panbela Therapeutics, Inc.繼續因經營活動蒙受虧損和負現金流,這使人們對其在沒有額外融資的情況下繼續經營的能力產生了嚴重懷疑。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息